The invention discloses a cannabinoid nano-micelle preparation and a preparation method thereof. The cannabinoid nano-micelle preparation includes cannabinoid and an amphiphilic polymer, wherein the content of the cannabinoid is 1-40% by weight, the content of the amphiphilic polymer is 1-99%, and the preparation method includes the following steps: (1) preparing a cannabinoid nano-micelle solution from cannabinoid and an amphiphilic polymer; (2) drying the micellar solution obtained in the step (1) to obtain cannabinoid nano-micelle powder; and (3) preparing the cannabinoid nano-micelle powder obtained in the step (2) into the cannabinoid nano-micelle preparation. The cannabinoid nano-micelle preparation is high in effective component wrapping rate and transfer rate, high in drug loading capacity and high in stability, and a novel normal-temperature self-assembly technology is adopted, so that an active component cannabinoid is prevented from being degraded and discolored at high temperature; the bioavailability of the active ingredient is high, and a single dose can be reduced. Especially, a dry powder inhalant is high in in-vitro deposition rate and quick in inhalation effect, and can provide continuous and stable blood concentration.

Provided herein are dry powder formulations comprising epinephrine alone or in combination with at least one enabling agent suitable for nasal application. Also provided are unit dose forms and devices comprising such formulations and methods of using such formulations for the treatment of various conditions including anaphylaxis, anaphylactoid reaction, respiratory conditions, hemodynamic collapse, and for administration during cardiopulmonary arrest and other life-threatening conditions.

A method of controlling or electing the harshness of inhaled nicotine powder formulations is described. The method includes the steps of identifying a concentration of nicotine for a subject to inhale to achieve a desired level of harshness per inhalation, identifying the total dose of nicotine to be inhaled by the subject, and providing the subject with an amount of a formulation comprising nicotine particles having the identified concentration of nicotine, such that the total amount of nicotine particles in the formulation equals the total dose of nicotine.

This invention relates to inhalable formulation comprising a macrocyclic, cavity-containing compound as a biologically active ingredient. The present invention relates also to an inhalable formulation comprising a macrocyclic, cavity-containing compound as a biologically active ingredient for use in a method of treating an infection in a subject. In addition, the present invention relates to a method of treating an infection in a subject by administering an inhalable formulation comprising a macrocyclic, cavity-containing compound as a biologically active ingredient to the subject. The inhalable formulation comprising a macrocyclic, cavity-containing compound as a biologically active ingredient is suitable for the treatment of pulmonary or systemic infections caused by Gram-positive or Gram-negative bacteria.

The invention provides a pharmaceutical composition and methods for the treatment of a respiratory disease that results from a viral infection. The pharmaceutical composition can include a peptide that interferes with the Src family kinase-Androgen receptor interaction (i.e., an “SA inhibitor”). The composition can also include Niacin or a Niacin derivative and/or a DNase I or fragment or derivative. The pharmaceutical composition can prevent the development of Acute Respiratory Distress Syndrome (ARDS) associated with Corona vims infection and allow the host adaptive immune response to overcome the infection.

A medicament for inhalation is provided. The medicament comprises at least a first layer comprising a first active pharmaceutical ingredient in powder form and at least a second layer comprising at least a second active pharmaceutical ingredient in powder form. The second layer is disposed on the first layer. A container for dispensing a medicament and methods of making are also described.

Disclosed herein are improved methods of treating hyperglycemia with a combination of an ultrarapid acting insulin and insulin glargine comprising prandial administration of the ultrarapid insulin, and administration of a first dose of insulin glargine within 6 hours of waking for a day.

The present disclosure relates to a pharmaceutical composition, such as a dry powder inhalation formulation or an injectable formulation, comprising a mixture of an antiviral agent and a mast cell stabilizer. The present disclosure relates to a codrug comprising a residue of an antiviral agent covalently bonded via a labile bond to a residue of a compound of Formula (I) or Formula (II). The present disclosure further relates to a method of administering an antiviral agent and a Formula I/II compound, a pharmaceutical composition, or a codrug to treat coronavirus infection and/or associated inflammation.

present disclosure relates to methods for relaxing airway smooth muscle tissue, alleviating or preventing bronchospasm, and treating lung diseases by administering an HMG-CoA reductase inhibitor (statin) directly to lung tissue by inhalation. The disclosure also relates to formulations and compositions useful for the practice of methods of the disclosure.

A respirable dry powder can include acetylsalicylic acid in particles having a mass median aerodynamic diameter (MMAD) within a range of about 0.5 μm to about 10 μm. The respirable dry powder may contain a pharmaceutically acceptable excipient, such as an amino acid (e.g., Leucine), in an amount ranging from about 0.1% (w/w) to about 40% (w/w) of the particles.